Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD)-based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis

Record Status
This is a systematic review that meets the criteria for inclusion on DARE. If you would like us to consider prioritising the writing of a critical abstract for this review please e-mail CRD-DARE@york.ac.uk quoting the Accession Number of this record. Please note that priority is given to fast track requests from the UK National Health Service.

Bibliographic details

PubMedID
24861981

DOI
10.1111/bjh.12946

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Boronic Acids /administration & dosage; Bortezomib; Clinical Trials, Phase III as Topic; Cyclophosphamide /administration & dosage; Dexamethasone /administration & dosage; Humans; Induction Chemotherapy; Middle Aged; Multiple Myeloma /drug therapy /pathology; Pyrazines /administration & dosage; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide /administration & dosage

AccessionNumber
12014034723

Date bibliographic record published
02/10/2014